BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 01, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Naluzotan: Phase II started

Proximagen disclosed in its 2Q11 earnings that NIH's National Institute of Neurological Disorders and Stroke (NINDS) began a double-blind, placebo-controlled, crossover, U.S. Phase II trial to evaluate 120 mg oral naluzotan twice daily in about 30 patients....

Read the full 163 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >